154 related articles for article (PubMed ID: 38254257)
1. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M; Hirasawa Y; Kuramasu A; Murayama M; Narikawa Y; Toyoda H; Baba Y; Isobe J; Funayama E; Tajima K; Shida M; Hamada K; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Horiike A; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Tsunoda T; Yoshimura K
Cancer Sci; 2024 Mar; 115(3):752-762. PubMed ID: 38254257
[TBL] [Abstract][Full Text] [Related]
2. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
Hall KH; Liu Y; Jiang C; Harvey RD
Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
[TBL] [Abstract][Full Text] [Related]
6. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
7. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells.
Gazzano M; Parizot C; Psimaras D; Vozy A; Baron M; Abbar B; Fallet V; Litvinova E; Canellas A; Birzu C; Pourcher V; Touat M; Weiss N; Demeret S; Roos-Weil D; Spano JP; Lebbe C; Salem JE; Cadranel J; Hervier B; Gorochov G; Guihot A
Front Immunol; 2022; 13():1082084. PubMed ID: 36605194
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
[TBL] [Abstract][Full Text] [Related]
10. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
11. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Yamamoto K; Makino T; Takahashi T; Kawashima A; Haruna M; Hirata M; Ueyama A; Iwahori K; Satoh T; Kurokawa Y; Eguchi H; Doki Y; Wada H
Cancer Immunol Immunother; 2023 Jan; 72(1):169-181. PubMed ID: 35776160
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.
Song SJ; Song YK; Jang M; Shin E; Suh SY; Cho YS; Lee JY; Oh JM
Target Oncol; 2023 Jan; 18(1):147-158. PubMed ID: 36515782
[TBL] [Abstract][Full Text] [Related]
13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
15. Significance of CD103
Natsuki S; Tanaka H; Nishiyama M; Deguchi S; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
BMC Cancer; 2023 Oct; 23(1):1011. PubMed ID: 37864146
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy.
Hou YZ; Zhang Q; Bai H; Wu T; Chen YJ
World J Clin Cases; 2023 Mar; 11(7):1458-1466. PubMed ID: 36926390
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
18. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
20. Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism.
Takahashi R; Sato Y; Kimishima M; Shiohara T; Ohyama M
Int J Clin Oncol; 2020 Oct; 25(10):1861-1869. PubMed ID: 32656742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]